Heparan sulfate modulates kinin release by Trypanosoma cruzi through the activity of cruzipain

被引:66
|
作者
Lima, APCA
Almeida, PC
Tersariol, ILS
Schmitz, V
Schmaier, AH
Juliano, L
Hirata, IY
Müller-Esterl, W
Chagas, JR
Scharfstein, J
机构
[1] Univ Brazil, Inst Biofis Carlos Chagas Filho, CCS, BR-21944900 Rio De Janeiro, Brazil
[2] Univ Mogi das Cruzes, Ctr Interdisciplinas Invest Bioquim, Sao Paulo, Brazil
[3] Univ Fed Estado Sao Paulo, Escola Paulista Med, Dept Biofis, Sao Paulo, Brazil
[4] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA
[5] Goethe Univ Frankfurt, Med Sch, Inst Biochem 2, D-60590 Frankfurt, Germany
关键词
D O I
10.1074/jbc.M108518200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Trypanosoma cruzi activates the kinin pathway through the activity of its major cysteine proteinase, cruzipain. Because kininogen molecules may be displayed on cell surfaces by binding to glycosaminoglycans, we examined whether the ability of cruzipain to release kinins from high molecular weight kininogen (HK) is modulated by heparan sulfate (HS). Kinetic assays show that HS reduces the cysteine proteinase inhibitory activity (K-i (app)) of HK about 10-fold. Conversely, the catalytic efficiency of cruzipain on kinin-related synthetic fluorogenic substrates is enhanced up to 6-fold in the presence of HS. Analysis of the HK breakdown products generated by cruzipain indicated that HS changes the pattern of HK cleavage products. Direct measurements of bradykinin demonstrated an up to 35-fold increase in cruzipain-mediated kinin liberation in the presence of HS. Similarly, kinin release by living trypomastigotes increased up to 10-fold in the presence of HS. These studies suggest that the efficiency of T. cruzi to initiate kinin release is potently enhanced by the mutual interactions between cruzipain, HK, and heparan sulfate proteoglyeans.
引用
收藏
页码:5875 / 5881
页数:7
相关论文
共 36 条
  • [31] Improving the drug-likeness of inspiring natural products - evaluation of the antiparasitic activity against Trypanosoma cruzi through semi-synthetic and simplified analogues of licarin A
    Morais, Thiago R.
    Alves Conserva, Geanne A.
    Varela, Marina T.
    Costa-Silva, Thais A.
    Thevenard, Fernanda
    Ponci, Vitor
    Fortuna, Ana
    Falcao, Amilcar C.
    Tempone, Andre G.
    Fernandes, Joao Paulo S.
    Lago, Joao Henrique G.
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [32] Anosmin-1 modulates fibroblast growth factor receptor 1 signaling in human gonadotropin-releasing hormone olfactory neuroblasts through a heparan sulfate-dependent mechanism
    González-Martínez, D
    Kim, SH
    Hu, YL
    Guimond, S
    Schofield, J
    Winyard, P
    Vannelli, GB
    Turnbull, J
    Bouloux, PM
    JOURNAL OF NEUROSCIENCE, 2004, 24 (46): : 10384 - 10392
  • [33] Crystal violet structural analogues identified by in silico drug repositioning present anti-Trypanosoma cruzi activity through inhibition of proline transporter TcAAAP069
    Saye, Melisa
    Gauna, Lucrecia
    Valera-Vera, Edward
    Reigada, Chantal
    Miranda, Mariana R.
    Pereira, Claudio A.
    PLOS NEGLECTED TROPICAL DISEASES, 2020, 14 (01): : 1 - 23
  • [34] Potassium channel opener CGS7184 modulates activity of mitochondria by Ca2+ release through ryanodine receptor
    Wrzosek, A.
    Tomaskova, Z.
    Ondrias, K.
    Lukasiak, A.
    Szewczyk, A.
    BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS, 2010, 1797 : 136 - 136
  • [35] Trypanosoma cruzi infection modulates in vivo expression of major histocompatibility complex class II molecules on antigen-presenting cells and T-cell stimulatory activity of dendritic cells strain-dependent manner
    Soto, CDA
    Mirkin, GA
    Solana, ME
    Cappa, SMG
    INFECTION AND IMMUNITY, 2003, 71 (03) : 1194 - 1199
  • [36] A vanadyl sulfate-bovine serum albumin complex stimulates the release of lipoprotein lipase activity from isolated rat fat pads through an increase in the cellular content of cAMP and myo-inositol 1,4,5-trisphosphate
    Motoyashiki, T
    Miyake, M
    Yoshida, A
    Morita, T
    Ueki, H
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 1999, 22 (08) : 780 - 786